Next Phase Newsletter

A venture capital firm based in Eastern USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the United States, Israel, and the United Kingdom.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in USA and China is focused on medical device technologies. The firm is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$40 million. Typical investment size ranges from US $500K – 5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however, it can aid in identifying strategic partners in the Chinese market. The firm has expertise in helping portfolio companies in China Strategy, market strategy, regulatory strategy, and exit strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company with offices in Eastern USA is currently making investments from its vintage 2013 fund and is looking to make equity investments into early stage medical devices and digital health companies. The firm’s investment size varies depending on the financial needs of the company and they generally participate in seed through series B rounds. To date, the firm has only made investments in companies throughout the United States though they are open to pursuing investments globally. The firm generally makes 1-2 new investment per year.

The firm is focused entirely on early stage medical devices and digital health. The firm is open to invest in all classes of medical devices and all indications and all areas of digital health. The firm generally looks to be the first round of institutional financing often investing in companies that have yet to fully develop their prototype. Companies the firm has invested in previously include devices for Orthopedics, Diagnostics, DNA Sequencing, Women’s Health, Diabetes, Imaging, and Active and Implantable Devices.

The firm is looking for companies whose market has barriers to entry, a quick path to proof of concept, and capital efficient operations. The firm looks for passionate founders and will evaluate management on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture subsidiary of a Japanese pharmaceutical is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year.

The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm with offices in USA and China is investing from its US$200 million fund with a focus on high-tech enterprises in China and Western countries. The firm seeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.

Within healthcare, the firm considers biomedicine, medical devices, and digital health. The firm is most interested in personalized medicine products with an angle to the China market. Within digital health, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.

The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm involved with a sovereign wealth fund is actively making investments. The firm generally makes longer term investments than a typical VC. The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, digital health, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based out of Eastern USA is focused on companies in the healthcare field with a preference for innovative technology-based companies in Medtech, Diagnostics, and Digital Health. For medical devices, The firm will invest in both PMA and 510k devices and prefers to see some clinical validation. The firm is currently looking for 2-3 investments to close out their second fund in the coming year, and is in the process of raising a third fund with a first close to take place in 2019. The firm is stage agnostic but most often first invests $1-3M in Series A-B and reserves funds for follow-on investments. Most of the firm’s investments have been in the US and Israel, but the firm is open to investing globally.

The firm invests in companies with medical device, diagnostics and digital health technologies, focusing on innovative companies that can revolutionize their space. The firm favors technology-based products, such as genomics-based diagnostics or high-tech medical devices. Within digital health, the firm is fairly open, but has an interest in companies developing tools for clinical trials and other products developed for payer networks or Big Pharma. The firm is also interested in digital health technologies for hard-to-reach patient populations, such as those suffering from mental health disorders or substance abuse. While fairly opportunistic with regards to indication, the firm is particularly interested in technologies in the COPD, pulmonary hypertension, orthopedic and neurological space as well as products using ablation to treat pain.

The firm wants to see a strong CEO and Board when making investments. While often a not a lead investor, the firm is very active and will frequently take a Board seat after investing. The firm is looking to lead more investments when investing from their third fund.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.